Get the latest news, insights, and market updates on CRVS (Corvus Pharmaceuticals, Inc.). Explore the news page 3 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.
Corvus Pharmaceuticals to Announce Results from Cohort 4 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis
Company to host conference call and webcast on Tuesday, January 20, 2026 at 8:00 am ET / 5:00 am PTSOUTH SAN FRANCISCO, Calif., Jan. 16, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, announced that it will host a conference call and webcast on Tuesday, January 20, 2026 at 8:00 am ET (5:00 am PT) to report the results from cohort 4 of the randomized, blinded, placebo-controlled Phase 1 clinical trial evaluating soquelitinib in pa Jan 16, 2026 - $CRVS
Corvus Pharmaceuticals Presents Final Data from Soquelitinib Phase 1/1b T Cell Lymphoma Trial
Patients in 200 mg BID cohort had median progression free survival of 6.2 months and median overall survival of 28.1 months, comparing favorably to results with other therapies Data supports ongoing registration Phase 3 trial in r/r PTCL, Phase 1 trial in atopic dermatitis and potential expansion into other immune and inflammatory diseases Highlights ITK inhibition novel mechanism of action affecting T cell receptor signaling and T cell differentiation Presented in an oral session at the 67th Am Dec 8, 2025 - $CRVS
Corvus: Q3 Earnings Snapshot
SOUTH SAN FRANCISCO, Calif. AP) — Corvus Pharmaceuticals Inc. CRVS) on Tuesday reported a loss of $10.2 million in its third quarter. Nov 4, 2025 - $CRVS
Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2025 Financial Results
Completed enrollment in soquelitinib atopic dermatitis Phase 1 trial extension cohort 4 (200 mg BID dose with 8-week treatment period) with data announcement anticipated in January Soquelitinib atopic dermatitis phase 2 trial on track to initiate in early Q1 2026 Phase 3 registrational clinical trial of soquelitinib in relapsed/refractory peripheral T cell lymphoma (PTCL) enrolling with multiple clinical sites open; final Phase 1/1b results accepted for oral presentation at the American Society Nov 4, 2025 - $CRVS
Corvus Pharmaceuticals to Present Final Data from Soquelitinib Phase 1/1b T Cell Lymphoma Trial at the 67th American Society of Hematology Annual Meeting & Exposition
SOUTH SAN FRANCISCO, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that final data from its Phase 1/1b trial of soquelitinib in patients with T cell lymphoma will be presented in an oral session at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition, which is taking place December 6-9, 2025 in Orlando, FL. Details regarding the oral presentation are as follows: Session Name: Nov 3, 2025 - $CRVS
Corvus Pharmaceuticals to Present at the Guggenheim 2nd Annual Healthcare Innovation Conference
SOUTH SAN FRANCISCO, Calif., Oct. 31, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that members of its leadership team will conduct one-on-one meetings with investors and participate in a fireside chat presentation at the Guggenheim 2nd Annual Healthcare Innovation Conference, which is being held in Boston, MA. The fireside chat will be on Monday, November 10, 2025 at 8:30 am ET. A webcast of the fireside chat w Oct 31, 2025 - $CRVS
Corvus Pharmaceuticals to Provide Business Update and Third Quarter 2025 Financial Results on November 4, 2025
Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PTSOUTH SAN FRANCISCO, Calif., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that the company will host a conference call and webcast on November 4, 2025 at 4:30 pm ET (1:30 pm PT) to provide a business update and report third quarter 2025 financial results. The conference call can be accessed by dialing 1-800-717-1738 (toll-free domesti Oct 28, 2025 - $CRVS
We use cookies and similar technologies to collect and process data such as browsing activity or unique identifiers.
Selecting "Allow All" to help us understand site usage and improve the platform.
Choosing "Essential Cookies Only" enables only the cookies necessary for core site functions, such as staying logged in.
For more information, please see our Privacy Policy.
Continue with Google
Continue with Facebook
Continue with Microsoft
Continue with Apple